Abstract
Focal amplifications in 6p21 containing the VEGFA locus occur in 7%-10% of hepatocellular carcinoma (HCC). A recent paper describes how VEGF-A stimulates paracrine secretion of hepatocyte growth factor by stromal cells, which induces tumor progression. HCC patients with VEGFA amplification are distinctly sensitive to sorafenib.
Copyright © 2014 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Hepatocellular / drug therapy*
-
Cell Proliferation
-
Disease Progression
-
Drug Resistance, Neoplasm*
-
Gene Amplification
-
Hepatocyte Growth Factor / metabolism
-
Humans
-
Liver Neoplasms / drug therapy
-
Macrophages
-
Mice
-
Niacinamide / analogs & derivatives*
-
Niacinamide / therapeutic use
-
Phenylurea Compounds / therapeutic use*
-
Sorafenib
-
Treatment Outcome
-
Vascular Endothelial Growth Factor A / genetics
-
Vascular Endothelial Growth Factor A / metabolism*
Substances
-
Antineoplastic Agents
-
Phenylurea Compounds
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Niacinamide
-
Hepatocyte Growth Factor
-
Sorafenib